2022年肝癌重点研究盘点

Inventory of key research on hepatocellular carcinoma in 2022

肝癌(HCC)是我国最为常见的消化系统肿瘤之一,多数病人就诊时处于进展期或晚期,预后差。2022年,多个关于肝癌治疗的大规模前瞻性临床研究结果公布,其中多项具有划时代意义。LAUNCH研究结果首次证实全身药物治疗联合局部治疗可以提高晚期HCC病人总生存期;中山大学肿瘤防治中心的研究结果提示,FOLFOX-HAIC作为术后辅助性治疗可改善微血管侵犯的肝癌病人预后。此外,多项免疫检查点抑制剂的研究,无论单药使用,或者联合方案均取得突破性的进展。这些临床研究的数据公布,对于调整肝细胞癌的治疗策略和药物选择具有较大的指导意义。此外,还有很多肝癌临床治疗问题,例如肝功能不全肝癌病人的药物选择等,均有待于进一步的研究探索。

Hepatocellular carcinoma(HCC)is one of the most common digestive malignant tumors in China,and most patients are in the progressive or advanced stage when they are diagnosed,with poor prognosis.In 2022,the results of several large-scale prospective clinical studies on the advanced hepatocellular carcinoma were published,many of which are of epoch-making significance.The LAUNCH study demonstrated for the first time that systemic drug therapy combined with regional therapy could improve the overall survival of patients with advanced HCC,while the study from the Sun Yat-sen University Cancer Center suggested that FOLFOX-HAIC as postoperative adjuvant therapy could improve the prognosis of HCC patients with microvascular invasion.In addition,several studies of immune checkpoint inhibitors,whether used as single agent in second line or in combination as the first-line therapy,have made breakthroughs.The clinical studies provide powerful guide for adjusting treatment strategies and drug selection in HCC.However,there are still many clinical treatment issues for HCC,such as drug selection for HCC patients with hepatic insufficiency,that need to be explored in further studies.